



Adverse consequences of neonatal antibiotic exposure

Charles M. Cotten

Purpose of review

Antibiotics have not only saved lives and improved outcomes, but they also influence the evolving microbiome. This review summarizes reports on neonatal infections and variation in antibiotic utilization, discusses the emergence of resistant organisms, and presents data from human neonates and animal models demonstrating the impact of antibiotics on the microbiome, and how microbiome alterations impact health. The importance of antibiotic stewardship is also discussed.

Recent findings

Infections increase neonatal morbidity and mortality. Furthermore, the clinical presentation of infections can be subtle, prompting clinicians to empirically start antibiotics when infection is a possibility. Antibiotic-resistant infections are a growing problem. Cohort studies have identified extensive center variations in antibiotic usage and associations between antibiotic exposures and outcomes. Studies of antibiotic-induced microbiome alterations and downstream effects on the developing immune system have increased our understanding of the mechanisms underlying the associations between antibiotics and adverse outcomes. The emergence of resistant microorganisms and recent evidence linking antibiotic practice variations with health outcomes has led to the initiation of antibiotic stewardship programs.

Summary

The review encourages practitioners to assess local antibiotic use with regard to local microbiology, and to adopt steps to reduce infections and use antibiotics wisely.

Keywords

antibiotic resistance, antibiotic stewardship, antibiotics, microbiome, neonate

INTRODUCTION

Humans are colonized with microorganisms which we coexist with in a mutualistic relationship. Microbes contribute to mechanisms that protect against colonization by pathogens, participate in maturation of the immune system, and provide key metabolic functions [1[■],2–4]. However, microbes also cause infections in neonates that result in significant mortality and neurodevelopmental impairment among survivors [5–6]. Clinicians have used antibiotics to prevent and treat infections resulting in millions of lives saved; however, with benefits come risks. Microorganisms develop mechanisms of resistance against antibiotics and transfer them to other microorganisms [7,8]. Genes conferring antibiotic resistance are present in the microbes inhabiting the intestine of preterm infants cared for in a neonatal ICU (NICU) environment as well as healthy term infants [9,10[■],11[■],12]. Antibiotic-resistant pathogenic microorganisms can cause serious, difficult-to-treat

infections in neonates [8]. Because of the impact of infections and the subtle clinical presentation of infection in neonates, exposure to antibiotics is unavoidable for many neonates, particularly those born prematurely. Epidemiologic evidence suggests associations between neonatal antibiotic exposures and short and long-term health outcomes. Through neonatal animal studies we are gaining an understanding of how antibiotic exposures influence the acquisition of microbial diversity in the neonatal period, and how these antibiotic-influenced alterations could impact microbiome-linked short and long-term health [1[■],13,14[■],15[■]].

Duke University School of Medicine, Durham, North Carolina, USA

Correspondence to Charles M. Cotten, MD, MHS, Duke University School of Medicine, Box 2739 DUMC, Durham, NC 27710, USA.

Tel: +1 919 681 4844; fax: +1 919 681 6065;

e-mail: cotte010@mc.duke.edu

Curr Opin Pediatr 2016, 28:141–149

DOI:10.1097/MOP.0000000000000338

KEY POINTS

- Antibiotics are often an unavoidable and sometimes life-saving part of neonatal clinical care.
- Antibiotic use by clinicians has been accompanied by bacterial development and sharing of antibiotic resistance.
- Prevalent empirical antibiotic use has been linked with subsequent risk of infections, NEC, and death.
- Understanding of the mechanisms linking the evolving microbiome, the developing immune system, and subsequent health in animal models is increasing.
- Antibiotic stewardship efforts, including increasing knowledge of the pharmacokinetics of antimicrobials, to optimize antimicrobial use have been successful.

This review will describe the extent and variation in antibiotic practice in NICUs, update information on infections caused by resistant organisms in neonates, and present evidence identifying associations between antimicrobial practice and short and long-term clinical outcomes. Because the biologic plausibility for these associations is based in part on the expanding knowledge of how antimicrobials influence the developing microbiome, we will summarize recent animal studies linking neonatal antibiotic exposure, microbiome variation, immune system development, and disease. Finally, because efforts to optimize antibiotic use in NICUs are underway, we will review emerging evidence of their effectiveness.

Rationale for preventive and empirical therapeutic use of antibiotics in neonates

In the modern era of antibiotics, which arguably began in September 1928 in the staphylococcal plate contaminated with *Penicillium notatum* in Alexander Fleming's laboratory [16], clinicians have used antibiotics therapeutically and prophylactically to save millions of lives. Particularly noteworthy for neonates, the incidence of early-onset Group B streptococcus (GBS; *Streptococci agalactiae*) sepsis has decreased 10-fold since 1996 when a risk-factor based preventive approach inclusive of antenatal and postnatal antibiotics was introduced. However, with this approach, approximately 30% of mothers in the United States are exposed to intrapartum antibiotics [17–22].

Early onset sepsis, even with GBS prophylaxis, affects a higher percentage of prematurely born infants than term infants [20]. Preterm infants, who stay for weeks in the NICU, remain at risk for

late onset sepsis [23²²]. The prematurely born neonatal population presents challenges because of imperfect skin and mucosal barriers, invasive procedures, and a partially effective immune system which relies largely on innate immunity and neutrophil function for defense against infection [24,25²²].

Infections occurring after the first postnatal days, which affect 20–40% of extremely preterm infants, are due predominantly to gram-positive bacteria (approximately 70–80%). Coagulase negative *Staphylococcus* (CONS), an oxacillin-resistant organism, is the most commonly isolated organism. Methicillin resistant staphylococcal (MRSA) infections are also on the rise. Gram-negative infections, particularly from enteric gram-negative bacilli, account for 10–20% of infections, and fungal species account for the remainder (approximately 10%) [5,8,23²²,26].

As a consequence of the GBS prevention guidelines, approximately 10% of the total neonatal population are exposed to antibiotics in the first postnatal days, and almost 100% of the extremely preterm population are exposed to ampicillin and an aminoglycoside [27–31,32²²]. The presentation of neonatal infections can be subtle, leading clinicians to empirically use antibiotics to avoid delay in treating true infections [27,31]. In a sample of over 200 NICUs, ampicillin, gentamicin, and vancomycin were the first, second, and fourth most commonly prescribed medications [32²²]. Although empirical antibiotic use is frequent, a review of over 1500 patients in one NICU revealed that only 5% of all neonatal antibiotic use was for culture proven infections [33].

Variations in antimicrobial practice

Centers vary widely in the use of antibiotics for neonates [28,34–36]. In a recent survey of guidelines for use of 41 antimicrobials in French NICUs, 1–32 different dosing regimens/drug were identified [37²²]. A 40-fold variation in NICU antibiotic prescribing practice was observed in a review of over 50 000 NICU patients in 127 California NICUs with similar burdens of proven infection, necrotizing enterocolitis (NEC), surgical volume, and mortality [38²²]. A review of antibiotic use in 89 NICUs participating in the European Study of Neonatal Exposure to Excipients identified variation in antibiotic dosing among the most commonly used antibiotics, with significant under and overdosing of antibiotics (based on dosing guidelines produced by the British National Formulary for Children) [39²²]. Underdosing of antibiotics leads to low concentrations of antibiotics, particularly at sites of

heavy microbial concentrations, such as mucosal surfaces and biofilms surrounding central lines, and increases the likelihood of developing resistant microbes [8,40].

Antibiotic resistance: emerging problem for neonatal infections

Mechanisms to develop antibiotic resistance include: acquisition of enzymes that alter antibiotic structure and function, mutations in bacterial targets such as penicillin-binding proteins, and changes in efflux pumps allowing removal of antibiotics from bacteria or porins which prevent antibiotics from entering bacteria [8]. With an awareness of resistance mechanisms, Harold Neu warned of complacency with regard to the threat of antimicrobial resistance. In 1992 he warned that bacteria had become resistant to antimicrobial agents as a result of chromosomal changes or the exchange of genetic material via plasmids and transposons. By 1992, gram-positive and gram-negative pathogens had become resistant to virtually all of the original generations of antibiotics. He hypothesized that extensive community and hospital-based use of antibiotics had fueled the problem. Furthermore, he suggested that antibiotic control programs, better hand washing, and other infection control practices, as well as more potent antibiotics, would need to be adopted and developed to limit resistance [7]. Neu's warnings and advice must be acknowledged by clinicians caring for neonates.

Dr Roger Soll responded to the California NICUs report on variations in antibiotic practice by identifying increases in antibiotic resistant microorganisms as a major threat and direct result of our overuse of antibiotics [41]. Doctors using data from the WHO, found that the proportion of *Escherichia coli*, *Klebsiella pneumoniae*, and *Staphylococcus aureus* resistant to commonly used antibacterial drugs exceeded 50% in many settings [42]. The U.S. Centers for Disease Control (CDC) estimated that more than 2 million people in the United States become ill annually and over 23 000 die as a result of resistant bacteria [43]. Continued and widespread use of antibiotics has generated strong selective pressure on microorganisms, favoring the emergence of resistant strains [44]. This is problematic as the prevalence of microbes with antibiotic resistance has reached critically high levels and antibiotic discovery efforts have reached critically low levels. Federal funding of antibacterial research is dwarfed by that of other disease areas [45].

Among gram-positive pathogens, the emergence of strains of GBS that are resistant to erythromycin and clindamycin have caused problems, especially

for women who are penicillin allergic [19]. More recently NICU infections caused by staphylococcal species have been more problematic. CONS and MRSA are common NICU pathogens. CONS usually require treatment with vancomycin, as does MRSA [46]. However, widespread use of vancomycin can lead to the development of vancomycin resistance, particularly with vancomycin-resistant enterococci, or VRE. VRE has been linked with higher mortality than vancomycin susceptible enterococci [47^{*}]. Unfortunately, extended spectrum β -lactamase-producing gram-negative pathogens that are resistant to cephalosporins have also emerged, as have gram-negative organisms resistant to piperacillin-tazobactam, aminoglycosides, and *Klebsiella* resistant to carbapenems such as meropenem [8,44,48].

Antibiotic practice Linked to neonatal ICU outcomes

In the last decade, single and multicenter reports have linked the use of broad spectrum antibiotics, particularly cephalosporins, with subsequent mortality and candida infections [35,49]. Studies have linked the number of days exposed to antibiotics with subsequent mortality, NEC and non-CONS infections [28,50,51]. As noted, highly prevalent use of vancomycin in NICUs and other hospital areas has been associated with high colonization rates and outbreaks of infections with VRE [47^{*}]. Infections may emanate from the intestine, the site of the development of resistant strains and transfer of resistance genes among microorganisms [52^{*}]. In one cohort of infants longitudinally followed through their NICU stay, sequencing identified detectable levels of the sepsis-causative organism in stool samples prior to disease onset for 82% of late-onset sepsis cases [53].

Antibiotic practice influences the microbiome

The diversity of the microbiome contributes to normal growth and development, including normal maturation of the immune system [2]. Before the associations between antimicrobial selection, duration and outcomes were known, investigators had ascribed the decreased intestinal microbial diversity in neonates with increased exposure to antibiotics in the first postnatal days [54–56]. More recently, using molecular sequencing approaches, early postnatal as well as prenatal antibiotic exposure for GBS prophylaxis has been associated with significant alterations of the microbial inhabitants on the intestine [57^{*},58^{*}]. A higher percentage of *Enterobacter* colonization and lower bacterial diversity were noted in preterm infants who

received 5–7 days of empirical antibiotics compared with those not exposed or exposed to shorter courses [59[■]]. Small longitudinal studies also point to increased colonization with proteobacteria, inclusive of *Enterobacter* spp., comprising the microbiota in infants who subsequently develop NEC [60,61]. Enterobacter species are often resistant to β -lactam antibiotics. The resistance genes against β -lactams are often carried in plasmids, which are easily transmitted between bacteria, so if there are more resistance-mechanism carrying bacteria in the intestine, the risk for an accumulation of resistance plasmids is increased. This phenomenon of development of resistance gene ‘clusters’ has been identified in swine that are routinely treated with antimicrobials. [59[■],62].

Of some consolation, recent reports suggest that microbiome diversity recovers over time after relatively short antibiotic courses used in the first postnatal days. Shorter courses of antibiotics (1–3 days vs 5–7 days), were associated with suppression and alteration of the microbiome for several weeks, but recovery occurred after the third postnatal week [59[■],63,64[■],65].

Antibiotics, the microbiome and longer-term effects

As information has emerged about associations between microbiome diversity and health, investigators have studied links between antibiotic exposures in the neonatal period and the development of immune-related diseases such as asthma. In a U.S. cohort of 1401 children, the association between neonatal antibiotic exposure and asthma was strongest for those with no asthma family history [65]. Such associations are compelling, and biologically plausible, and fit with the hygiene hypothesis [66]. A systematic review of 20 studies identified the potential for bias, but concluded that early antibiotics, and even prenatal antibiotic exposures, ‘seemed to slightly increase the risk of childhood asthma’ [67]. A subsequent meta-analysis of over 40 studies concluded that ‘truly indicated antibiotics should not be withheld from infants or young children for fears they might develop asthma’ [68]. Subsequent studies of large population-based cohorts continue to indicate that there may be associations, but evidence is not overwhelming. Swedish investigators have reported a positive association between antibiotic exposure in fetal life or childhood and subsequent asthma in a National Birth cohort; however, in sibling control analyses, associations disappeared or decreased, indicating that factors shared by the families may be influencing the association [69[■]].

More recent cohort studies have assessed associations between early antibiotic exposure and other long-term health outcomes. One study examining the association between antibiotic exposures in the first postnatal year and subsequent asthma ($n=79\,946$) demonstrated that more antibiotic exposure was associated with subsequent higher BMI in boys [70]. In population-based studies in Denmark and the United States, accumulating antibiotic exposures, particularly antianaerobic medications, throughout the early years (not limited to neonatal exposures) were associated with subsequent inflammatory bowel disease and celiac disease [71–73]. These associations are of interest; however, cause and effect cannot be inferred as the antibiotic courses could be a marker of clinicians’ responses to the natural history of the disease [73].

A recent animal model study suggests an association between antibiotic alterations of microbial colonization and type 1 diabetes. In this experiment, a combination of broad-spectrum antibiotics or vancomycin alone was given to neonatal non-obese diabetic mice that spontaneously develop autoimmune type 1 diabetes. The antibiotic-treated male animals developed higher rates of diabetes. The microbiome was ablated in the combination treated group, and was significantly altered by vancomycin. Among the changes in microbiome that occurred with vancomycin were increased *Escherichia* and *Lactobacillus* genera, and decreased members of the Clostridiales order compared with controls. Along with the microbiome alterations, a major reduction of IL-17-producing cells was observed in the lamina propria of the ileum and the colon of vancomycin-treated mice [14[■]].

The mechanism linking antimicrobials, microbiome, and disease could be via the disruption of the interactions of specific microbiome microorganisms, and ‘first responder’ immune cells in the ileal lamina propria [14[■]]. The discovery of a connection between antibiotics and the suppression of IL-17-producing T cells (Th17) led to an understanding of the importance of segmented filamentous bacterium (SFB) on the differentiation of the Th17 cells. SFB are nonculturable Clostridia-related species. In studies of germ-free mice, colonization with SFB alone could recapitulate coordinated maturation of a wide range of both pro and regulatory T-cell responses induced by the whole mouse microbiota. This led investigators to hypothesize that SFB, already known as a potent inducer of mucosal immunoglobulin A (IgA), likely play a unique role in the postnatal maturation of gut immune functions. The low-level production of IL-17 stimulated by SFB, may optimize local protective bactericidal

mechanisms and reduce infection risk in immunocompetent hosts by inducing production of antiinfective compounds (such as IgA) and helping to maintain a sufficient number of neutrophils to contain potential invading pathogens. In addition, SFB, in contrast to most culturable intestinal flora, develop tight junctions with the luminal surface of the small intestine. The tight adherence may strengthen barrier function [74,75]. Although the data linking antibiotic use with T-cell subset suppression, and the importance of SFBs in the maturation of intestinal immunity is of interest, these theories have yet to be validated in human neonates.

Microbiome alterations and developing immune system

For neonates, particularly those born extremely prematurely, immune cell synthesized antibiotic proteins and neutrophils are key aspects of neonatal immune system defense [24,25²²]. In a piglet model, treatment with antibiotics reduced the diversity of gut microbiota and the expression of a large number of immune-related genes [76]. Recent investigations have identified links between the developing gut microbiome in the neonatal period and increases in circulating protective neutrophils postnatally [15²²,77]. In a neonatal rodent model, treatment with postnatal antibiotics decreased the quantity and diversity of microbes in the newborn animal's intestine, which may be beneficial if further pathogen exposure could be avoided. However, when normal colonization by γ -proteobacteria and subsequent granulocytosis were inhibited, the likelihood of sepsis after exposure to *E coli* and *Klebsiella* administered after the microbiome-altering antimicrobial course was increased. The mechanism appears to be related to decreased TLR4 receptor stimulation following microbiome alteration which leads to downstream decreases in IL-17A and G-CSF production [15²²]. This suggests an antibiotic-linked mechanism which places infants at higher risk of infection via intestinal translocation to a neutrophil-depleted environment after antibiotic exposure. Thus, as in the earlier description of the interactions between segmented filamentous bacteria and T-cell development, it is of interest that the intestinal microbiome may be a source of both immune protection, and organisms responsible for late-onset sepsis [78].

Antibiotic practice modifications/stewardship efforts

Although investigations of mechanisms of how the microbiome influences neonatal health are ongoing, clinicians make daily antibiotic decisions

for thousands of infants. Clinicians choose which infants to treat, what to treat with, and how long to treat.

Who to treat?

Efforts to improve the accuracy of which neonates to empirically treat with antibiotics include the development of an on-line tool to quantify risk of early-onset sepsis among term and near term infants [29,79²²,80]. The online tool includes consideration of population prevalence of early-onset sepsis, maternal clinical signs and GBS colonization status, and the neonate's clinical signs. Application of such a guideline could result in decreased antibiotic treatment in 80 000–240 000 U.S. newborns each year [79²²].

Biomarkers from blood testing, including cytokines and cell surface markers, are not only promising, but are most helpful for their negative predictive value [81]. Two recent reports suggest that gene expression patterns may distinguish infected from uninfected neonates. These efforts may eventually aid in the detection of truly infected neonates, but in the shorter term will help us better understand variations and mechanisms of the neonatal immune response [82,83²²]. For these blood sampling-based approaches, clinical suspicion must exceed a threshold that drives clinicians to order the test.

For neonates in the NICU, use of heart rate characteristics, to help determine who to empirically treat for sepsis, appears to be helpful [84,85²²]. In the multicenter randomized trial of visible results from heart rate characteristic monitoring vs blinded data collection, 30-day mortality among infected infants was 10% among those with displayed heart rate characteristics, and 16% among controls ($P=0.01$). Investigators also found that the number of sepsis work-ups and days of antibiotics total in both groups were similar [86].

What to use?

Some clinicians choose oxacillin or similar antibiotics for empirical therapy for late onset sepsis, and reserve the use of vancomycin for when cultures are positive. Others may choose to use vancomycin for empirical therapy due to the relatively high prevalence of CONS infections in many NICUs. The choice for gram-negative coverage is frequently an aminoglycoside, but some clinicians can be driven by concerns that these organisms can cause meningitis, leading to the use of cephalosporins [27,32²²].

Although debate surrounds the choice for empirical coverage for early and late-onset sepsis in NICUs, a cohort study of infants with positive cultures for *E. coli* ($n=267$) revealed that when empirical therapy did not include an antimicrobial

agent against the infecting *E. coli* strain, it was not associated with increased 30-day mortality. This suggests that initial empirical treatment with aminoglycosides, and later treatment with more potent, broader spectrum antibiotics, may be well tolerated [87]. Similar results were observed with studies of infants with CONS, where mortality outcomes were not improved with empirical vancomycin started before culture results were available [88]. A similar look suggested a benefit for empirical vancomycin when MRSA caused the infection, but screening strategies may identify infants at risk for MRSA and allow for selective use of empirical vancomycin [89[■]].

How to dose?

Gentamicin dosing is frequently guided by the assessment of peak and trough levels. Although over 80% of empirically selected doses result in effective and nontoxic levels, preterm infants exhibit variation in pharmacokinetics [90]. Only in the last year have we had dosing guidance for ampicillin derived from pharmacokinetics studied in a NICU cohort [91[■]]. Vancomycin pharmacokinetics have also recently been examined, and modifications in dosing based on individual variations may result in more infants reaching targeted trough levels [92[■],93]. Work by the Pediatric Trials Network has identified dosing regimens based on gestational and postnatal age for piperacillin tazobactam, metronidazole, meropenem, and antifungals [94[■],95–97,98[■]].

How long to treat?

Benitz and colleagues [99] have provided an approach for preterm and term infants at risk for early-onset sepsis. Among the key recommendations which could limit antibiotic use, and is concordant with the latest recommendation by members of the American Academy of Pediatrics (AAP) Committee on Fetus and Newborn, is that isolated abnormal hematological or acute-phase-reactant measurements should not justify continuation of empiric antibiotics for more than 48 h in well appearing infants with negative culture results [99,100]. We await similar evidence to support guidance for late-onset sepsis in NICUs.

IMPACT OF STEWARDSHIP

Although antibiotic stewardship continues to be a priority [101], use of antibiotics is likely to remain high among the neonatal population. As the Vermont Oxford Network's 'Choosing Antibiotics Wisely' program begins, we can be heartened by a reduction in candidiasis which is correlated to both increases in fluconazole prophylaxis and decreased

Table 1. US Centers for Disease Control 2013 core principles

Preventing infections and preventing the spread of resistance
Tracking resistant bacteria
Improving the use of today's antibiotics
Promoting the development of new antibiotics and developing new diagnostic tests for resistant bacteria

empirical use of broad spectrum antibiotics, particularly cephalosporins [102,103]. In the single center report on VRE mentioned earlier, colonization with vancomycin-resistant organisms decreased over a period of strict use guidelines for vancomycin. Vancomycin resistance increased as adherence to guidelines waned [47[■]].

In addition to choice of antibiotics, another recommendation by Neu was to pay closer attention to hand hygiene [7]. Single and multicenter efforts have reduced the incidence of central line-associated blood stream infections, which should lead to decreased antibiotic exposures, but better diagnostic methodologies may be needed before clinicians will significantly reduce empirical treatment, particularly for preterm infants [104–108]. The CDC has provided four core principles (Table 1) to put in place to reduce the development of resistant organisms, inclusive of considerations for improved hygiene [7,43]. To this list, we would add improvement in diagnostic test sensitivity and optimizing dosing information.

CONCLUSION

Antibiotics are an unavoidable fact of neonatal life. However, antibiotics are most often used in infants who are not infected. Their use has wide variations and neonatal-specific pharmacokinetic data on many antimicrobials are increasing, but for most antimicrobials are lacking. Evidence from animal studies linking antibiotic use in the neonatal period to variation in the evolving microbiome which impacts immune development and subsequent health, is emerging, but associations between antibiotic use early in postnatal life in humans and later complex common diseases such as asthma have not been strengthened (or refuted) by epidemiologic studies. More acutely, organisms responsible for late-onset sepsis in neonates may be more likely to emerge and invade via selection influenced, at least in part, by early antimicrobial practice variations (choice of antibiotic, dose used, duration used), and possibly by effects on the local immune and barrier defenses in the intestine. Increasing knowledge of antimicrobial pharmacokinetics will

help avoid the underdosing that contributes to the development of resistant microorganisms. Selective use of antibiotics through evidence-based antibiotic stewardship programs is also likely to help, as will clinical approaches that appear to be effective at reducing the occurrence of any infections.

Acknowledgements

There were no other direct contributors to this work; however, I would like to acknowledge three groups for the contributions to this field: first, Colleagues in the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network whose ongoing commitment to collecting epidemiologic data and reporting outcomes has provided important information to clinicians for decades, particularly Dr Barbara Stoll; second, the ongoing commitment of my colleagues in the Best Pharmaceuticals for Children Act–Pediatric Trials Network Administrative Core Committee, particularly P. Brian Smith and Daniel K. Benjamin, Jr. for their ongoing commitment to completing the important pharmacokinetic trials in neonates and other pediatric populations, which will greatly improve our ‘wise use’ of antibiotics in the neonatal population; and third) the leadership of the Pediatric medical group, Drs. Alan Spitzer and Reese Clark who have been very willing to share their data with colleagues to conduct the retrospective cohort studies which have revealed our variations in practice and reflect our ability to make changes and improve outcomes.

Financial support and sponsorship

C.M.C. received no funding specifically related to this article. He received funding from the National Institutes of Health: 5U10 HD040492-10, 1R01 HL105702 01A1, and 5R01-GM108494-02.

Conflicts of interest

C.M.C. has received support for his service on a data safety monitoring board for a clinical trial sponsored by rEVO pharmaceuticals (ClinicalTrials.gov: NCT02059135). C.M.C. has served on an advisory board for GW Pharmaceuticals.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Zeissig S, Blumberg RS. Life at the beginning: perturbation of the microbiota ■ by antibiotics in early life and its role in health and disease. *Nat Immunol* 2014; 15:307–310.

The complex interactions of host–microbiome clinician are introduced in this very understandable review. The authors present examples of how interventions that impact the microbiome impact subsequent health outcomes. They also expand on the hygiene hypothesis and present the ‘microbe’ hypothesis in which exposures to organisms that have coevolved with humans have been curtailed by antibiotics and possibly vaccines, and subsequent infection with other organisms in their place adds to risk of autoimmune disease.

2. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. *Science* 2012; 336:1268–1273.
3. Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. *Nature* 2012; 489:242–249.
4. Putignani L, Del Chierico F, Petrucca A, *et al.* The human gut microbiota: a dynamic interplay with the host from birth to senescence settled during childhood. *Pediatr Res* 2014; 76:2–10.
5. Stoll BJ, Hansen N, Fanaroff AA, *et al.* Late-onset sepsis in VLBW neonates: the experience of the NICHD Neonatal Research Network. *Pediatrics* 2002; 110:285–291.
6. Stoll BJ, Hansen NI, Adams-Chapman I, *et al.* Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. *JAMA* 2004; 292:2357–2365.
7. Neu H. The crisis in antibiotic resistance. *Science* 1992; 257:1064–1073.
8. Patel SJ, Saiman L. Antibiotic resistance in neonatal intensive care unit pathogens: mechanisms, clinical impact, and prevention including antibiotic stewardship. *Clin Perinatol* 2010; 37:547–563.
9. LaTuga MS, Ellis JC, Cotton CM, *et al.* Beyond bacteria: a study of the enteric microbial consortium in extremely low birth weight infants. *PLoS One* 2011; 6:e27858.
10. Fouhy F, Ogilvie LA, Jones BV, *et al.* Identification of aminoglycoside and ■ β-lactam resistance genes from within an infant gut functional metagenomic library. *PLoS One* 2014; 9:e108016.

See annotation for [11[■]].

11. Brooks B, Firek BA, Miller CS, *et al.* Microbes in the neonatal intensive care ■ unit resemble those found in the gut of premature infants. *Microbiome* 2014; 2:1.

This, and the report by Fouhy *et al.* [10[■]], are among the first reports correlating species specificity of gut microbiome matched with organisms responsible for late-onset sepsis in NICU patients.

12. Moore AM, Ahmadi S, Patel S, *et al.* Gut resistome development in healthy twin pairs in the first year of life. *Microbiome* 2015; 3:27.
13. Schokker D, Zhang J, Zhang LL, *et al.* Early-life environmental variation affects intestinal microbiota and immune development in new-born piglets. *PLoS One* 2014; 9:e100040.
14. Candon S, Perez-Arroyo A, Marquet C, *et al.* Antibiotics in early life alter the ■ gut microbiome and increase disease incidence in a spontaneous mouse model of autoimmune insulin-dependent diabetes. *PLoS One* 2015; 10:e0125448.

The report of an animal model of diabetes includes a thorough introduction to the concept of the microbiome developmental immune system disruptions linked to antibiotic use, particularly vancomycin, in a neonatal animal model.

15. Deshmukh HS, Liu Y, Menkiti OR, *et al.* The microbiota regulates neutrophil ■■ homeostasis and host resistance to *Escherichia coli* K1 sepsis in neonatal mice. *Nat Med* 2014; 20:524–530.

Antibiotic exposure of dams decreased the total number and composition of microbes in the intestine of neonates. This was associated with decreased numbers of circulating and bone marrow neutrophils and granulocyte/macrophage-restricted progenitor cells in the bone marrow of antibiotic-treated and germ-free neonates, which led to increased susceptibility to gram-negative sepsis. Transfer of a normal microbiota into antibiotic-treated neonates induced IL-17 production by group 3 innate lymphoid cells in the intestine, increasing plasma G-CSF levels and neutrophil numbers in a Toll-like receptor 4 – and myeloid differentiation factor 88 – dependent manner and restored IL-17-dependent resistance to sepsis. This study is one of several recent reports linking microbes, intestinal lymphoid cells, and a ‘steady state’-type immune response that provides protection against infection.

16. Trueman CN. Antibiotics. *Historylearningsite.co.uk*. The History Learning Site <http://www.historylearningsite.co.uk/a-history-of-medicine/antibiotics/17> Mar 2015. [Accessed 17 December 2015]
17. Schuchat A, Zywicki SS, Dinsmoor MJ, *et al.* Risk factors and opportunities for prevention of early-onset neonatal sepsis: a multicenter case-control study. *Pediatrics* 2000; 105:21–26.
18. Van Dyke MK, Phares CR, Lynfield R, *et al.* Evaluation of universal antenatal screening for group B streptococcus. *New Engl J Med* 2009; 360:2626–2636.
19. Verani JR, McGee L, Schrag SJ. Prevention of perinatal group B streptococcal disease—revised guidelines from CDC, 2010. *MMWR Recomm Rep* 2010; 59:1–36.
20. Stoll BJ, Hansen NI, Sanchez PJ, *et al.* Early onset neonatal sepsis: the burden of group B Streptococcal and *E. coli* disease continues. *Pediatrics* 2011; 127:817–826.
21. Weston EJ, Pondo T, Lewis MM, *et al.* The burden of invasive early-onset neonatal sepsis in the United States, 2005–2008. *Pediatr Infect Dis J* 2011; 30:937–941.
22. Bauserman MS, Laughon MM, Hornik CP, *et al.* Group B Streptococcus and *Escherichia coli* infections in the intensive care nursery in the era of intrapartum antibiotic prophylaxis. *Pediatr Infect Dis J* 2013; 32:208–212.
23. Stoll BJ, Hansen NI, Bell EF, *et al.* Trends in care practices, morbidity, and ■■ mortality of extremely preterm neonates, 1993–2012. *JAMA* 2015; 314:1039–1051.

The NICHD Neonatal Network provides a periodic report of morbidity and mortality among very preterm infants from a consortium of academic tertiary centers. In this latest report, the prevalence of late-onset sepsis is over 20%, but appears to have been decreasing over the last 5–10 years.

24. Wynn JL, Wong HR. Pathophysiology and treatment of septic shock in neonates. *Clin Perinatol* 2010; 37:439–479.
25. Cuenca AG, Wynn JL, Moldawer LL, Levy O. Role of innate immunity in neonatal infection. *Am J Perinatol* 2013; 30:105–112.
- The excellent review provides a description of the developing immune system of neonates, and serves as a starting point to understand links between the microbiome, the host, and impact of choices made by clinicians.
26. Stoll BJ, Gordon T, Korones SB, *et al.* Late-onset sepsis in very low birth-weight neonates: a report from the NICHD Neonatal Research Network. *J Pediatr* 1996; 129:63–71.
27. Gerdes JS. Diagnosis and management of bacterial infections in the neonate. *Pediatr Clin North Am* 2004; 51:939–959.
28. Cotten CM, Taylor S, Stoll B, *et al.* Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. *Pediatrics* 2009; 123:58–66.
29. Puopolo KM, Draper D, Wi S, *et al.* Estimating the probability of neonatal early-onset infection on the basis of maternal risk factors. *Pediatrics* 2011; 128:e1155–e1163.
30. Mukhopadhyay S, Eichenwald EC, Puopolo KM. Neonatal early-onset sepsis evaluations among well appearing infants: projected impact of changes in CDC GBS guidelines. *J Perinatol* 2013; 33:198–205.
31. Fanaroff AA, Korones SB, Wright LL, *et al.* Incidence, presenting features, risk factors and significance of late onset septicemia in very low birth weight infants. The National Institute of Child Health and Human Development Neonatal Research Network. *Pediatr Infect Dis J* 1998; 17:593–598.
32. Hsieh EM, Hornik CP, Clark RH, *et al.* Best Pharmaceuticals for Children Act: Pediatric Trials Network. Medication use in the neonatal intensive care unit. *Am J Perinatol* 2014; 31:811–821.
- In the second report from the Pediatric medical group, antibiotics remain three of the four most frequently prescribed medications in the NICU.
33. Cantey JB, Wozniak PS, Sanchez PJ. Prospective surveillance of antibiotic use in the neonatal intensive care unit: results from the SCOUT study. *Pediatr Infect Dis J* 2015; 34:267–272.
34. Cordero L, Ayers LW. Duration of empiric antibiotics for suspected early-onset sepsis in extremely low birth weight infants. *Infect Control Hosp Epidemiol* 2003; 24:662–666.
35. Cotten CM, McDonald S, Stoll B, *et al.* The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. *Pediatrics* 2006; 118:717–722.
36. Yakub SY, Constance JE, Stockmann C, *et al.* Epidemiological evaluation of blood culture patterns among neonates receiving vancomycin. *Indian J Microbiol* 2014; 54:389–395.
37. Leroux S, Zhao W, Bêtrémieux P, *et al.* Therapeutic guidelines for prescribing antibiotics in neonates should be evidence-based: a French national survey. *Arch Dis Child* 2015; 100:394–398.
- As in the United States, antimicrobial practice in NICUs varies widely. In an era of increasing attention to antibiotic stewardship, this information should stimulate and encourage increased high-quality pharmacokinetic studies of antimicrobials for neonates, and more standardized approaches, with careful and collective observation of results while awaiting those informative pharmacokinetic studies.
38. Schulman J, Dimand RJ, Lee HC. Neonatal intensive care unit antibiotic use. *Pediatrics* 2015; 135:826–833.
- NICUs vary extremely widely in their use of antibiotics. This report from the California Quality Collaborative indicates that, along with our colleagues in Europe, we have not arrived at a consensus use of antibiotics, from who to treat, what to treat with, and what doses to use. This report has given special impetus to initiate the Vermont–Oxford ‘using antibiotics wisely’ quality improvement initiative in 2016.
39. Metsvaht T, Nellis G, Varendi H, *et al.* High variability in the dosing of commonly used antibiotics revealed by a Europe-wide point prevalence study: implications for research and dissemination. *BMC Pediatr* 2015; 15:41.
- In addition to the report from France, this report from the UK also demonstrates extensive variation in antimicrobial practice, and reinforces the need for more data and a more standardized approach along with data gathering on outcomes.
40. Choffnes ER, Relman DA, Mack A. Antibiotic Resistance: Implications for Global Health and Novel Intervention Strategies: Workshop Summary (Free Summary) <http://www.nap.edu/catalog/12925.html> From: Courvalin (2010).
41. Soll RF, Edwards WH. Antibiotic use in neonatal intensive care. *Pediatrics* 2015; 135:928–929.
42. World Health Organization. Antimicrobial resistance: global report on surveillance (2014): http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf. [Accessed 23 December 2015]
43. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. Available at: www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. [Accessed 4 December 2015]
44. Tzialla C, Borghesi A, Pozzi M, Stronati M. Neonatal infections due to multiresistant strains: epidemiology, current treatment, emerging therapeutic approaches and prevention. *Clin Chim Acta* 2015; 451(Pt A):71–77.
45. Tomaras AP, Dunman PM. In the midst of the antimicrobial discovery conundrum: an overview. *Curr Opin Microbiol* 2015; 27:103–107.
46. Gray JW, Patel M. Management of antibiotic-resistant infection in the newborn. *Arch Dis Child Educ Pract Ed* 2011; 96:122–127.
47. Iosifidis E, Evdoridou I, Agakidou E, *et al.* Vancomycin-resistant Enterococcus outbreak in a neonatal intensive care unit: epidemiology, molecular analysis and risk factors. *Am J Infect Control* 2013; 41:857–861.
- Vancomycin-resistant enterococcus is a growing problem in tertiary care centers in which vancomycin is frequently, and often unavoidably, used. Careful cohorting and infection control measures, as well as antimicrobial stewardship efforts, were used to reduce the threat from this resistant organism.
48. Smith A, Saiman L, Zhou J, *et al.* Concordance of gastrointestinal tract colonization and subsequent bloodstream infections with gram-negative bacilli in very low birth weight infants in the neonatal intensive care unit. *Pediatr Infect Dis J* 2010; 29:831–835.
49. Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Empiric use of ampicillin and cefotaxime, compared with ampicillin and gentamicin, for neonates at risk for sepsis is associated with an increased risk of neonatal death. *Pediatrics* 2006; 117:67–74.
50. Kuppala VS, Meinen-Derr J, Morrow AL, Schibler KR. Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants. *J Pediatr* 2011; 159:720–725.
51. Alexander VN, Northrup V, Bizzarro MJ. Antibiotic exposure in the newborn intensive care unit and the risk of necrotizing enterocolitis. *J Pediatr* 2011; 159:392–397.
52. Carl MA, Ndao IM, Springman AC, *et al.* Sepsis from the gut: the enteric habitat of bacteria that cause late-onset neonatal bloodstream infections. *Clin Infect Dis* 2014; 58:1211–1218.
- As in the Brooks reference [11], this paper documents links between the intestinal flora and organisms that cause late-onset sepsis in the NICU.
53. Taft DH, Ambalavanan N, Schibler KR, *et al.* Center variation in intestinal microbiota prior to late-onset sepsis in preterm infants. *PLoS One* 2015; 10:e0130604.
54. Gewolb IH, Schwalbe RS, Taciak VL, *et al.* Stool microflora in extremely low birthweight infants. *Arch Dis Child Fetal Neonatal Ed* 1999; 80:F167–F173.
55. Fanaro S, Chierici R, Guerrini P, Vigi V. Intestinal microflora in early infancy: composition and development. *Acta Paediatr Suppl* 2003; 91:48–55.
56. Penders J, Thijs C, Vink C, Stelma FF, *et al.* Factors influencing the composition of the intestinal microbiota in early infancy. *Pediatrics* 2006; 118:511–521.
57. Arboleya S, Sánchez B, Milani C, *et al.* Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics. *J Pediatr* 2015; 166:538–544.
- One of the most recent studies to report on the neonatal microbiome using molecular methodologies. In their cohort of 27 preterm and 13 term infants tested over the first perinatal months, perinatal antibiotics, including intrapartum antimicrobial prophylaxis, affects the gut microbiota, as indicated by increased Enterobacteriaceae family organisms in the infants.
58. Fouhy F, Guinane CM, Hussey S, *et al.* High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parental antibiotic treatment with ampicillin and gentamicin. *Antimicrob Agents Chemother* 2012; 56:5811–5820.
- Early antibiotics exhibit what could be a transient effect on the diversity and content of the intestinal microbiome of neonates.
59. Greenwood C, Morrow AL, Lagomarcino AJ, *et al.* Early empiric antibiotic use in preterm infants is associated with lower bacterial diversity and higher relative abundance of Enterobacter. *J Pediatr* 2014; 165:23–29.
- In one of the largest cohorts of preterm infants tested for microbiome diversity ($n = 74$), antibiotics early in postnatal life had a substantial effect on the content and diversity of the developing microbiome, with increased relative abundance of Enterobacter and lower bacterial diversity in the first few postnatal weeks.
60. Mai V, Young CM, Ukhanova M, *et al.* Fecal microbiota in premature infants prior to necrotizing enterocolitis. *PLoS ONE* 2011; 6:e20647.
61. Claud EC, Keegan KP, Bruic L, *et al.* Bacterial community structure and functional contributions to emergence of health or necrotizing enterocolitis in preterm infants. *Microbiome* 2013; 1:20–31.
62. Looft T, Johnson TA, Allen HK, *et al.* In-feed antibiotic effects on the swine intestinal microbiome. *Proc Natl Acad Sci* 2012; 109:1691–1696.
63. Dardas M, Gill SR, Grier A, *et al.* The impact of postnatal antibiotics on the preterm intestinal microbiome. *Pediatr Res* 2014; 76:150–158.
64. Stewart CJ, Skeath T, Nelson A, *et al.* Preterm gut microbiota and metabolism following discharge from intensive care. *Sci Rep* 2015; 5:17141.
- This report is one of the first to concurrently report microbiome and metabolomics data in the NICU population. This area of linking NICU microbiome and metabolomic evolution will potentially yield important novel information about nutrition, substrate use and growth in NICU patients.
65. Risnes KR, Belanger K, Murk W, Bracken MB. Antibiotic exposure by 6 months and asthma and allergy at 6 years: findings in a cohort of 1401 US children. *Am J Epidemiol* 2011; 173:310–318.
66. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. *N Engl J Med* 2002; 347:911–920.
67. Murk W, Risnes KR, Bracken MB. Prenatal or early-life exposure to antibiotics and risk of childhood asthma: a systematic review. *Pediatrics* 2011; 127:1125–1138.
68. Heintze K, Petersen KU. The case of drug causation of childhood asthma: antibiotics and paracetamol. *Eur J Clin Pharmacol* 2013; 69:1197–1209.

69. Örtqvist AK, Lundholm C, Kieler H, *et al.* Antibiotics in fetal and early life and subsequent childhood asthma: nationwide population based study with sibling analysis. *BMJ* 2014; 349:g6979.
- The association also identified associations between early antimicrobials and asthma later in life; however, the sibling analysis found little likelihood of an antimicrobial effect.
70. Murphy R, Stewart AW, Braithwaite I, *et al.* Antibiotic treatment during infancy and increased body mass index in boys: an international cross-sectional study. *Int J Obes (Lond)* 2014; 38:1115–1119.
71. Hviid A, Svanström H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. *Gut* 2011; 60:49–54.
72. Kronman MP, Zaoutis TE, Haynes K, *et al.* Antibiotic exposure and IBD development among children: a population-based cohort study. *Pediatrics* 2012; 130:e794–e803.
73. Mårdild K, Ye W, Lebowitz B, *et al.* Antibiotic exposure and the development of coeliac disease: a nationwide case-control study. *BMC Gastroenterol* 2013; 13:109.
74. Gaboriau-Routhiau V, Rakotobe S, Lécuyer E, *et al.* The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. *Immunity* 2009; 31:677–689.
75. Mazmanian SK. Gut immune balance is as easy as S-F-B. *Immunity* 2009; 31:536–538.
76. Schokker D, Zhang J, Zhang LL, *et al.* Early-life environmental variation affects intestinal microbiota and immune development in new-born piglets. *PLoS ONE* 2014; 9:e100040.
77. Thanabalasuriar A, Kubes P. Neonates, antibiotics and the microbiome. *Nat Med* 2014; 20:469–470.
78. Shaw AG, Sim K, Randell P, *et al.* Late-onset bloodstream infection and perturbed maturation of the gastrointestinal microbiota in premature infants. *PLoS One* 2015; 10:e0132923.
79. Escobar GJ, Puopolo KM, Wi S, *et al.* Stratification of risk of early-onset sepsis in newborns >34 weeks' gestation. *Pediatrics* 2014; 133:30–36.
- Population-based statistical modeling of neonatal early-onset sepsis risk provides a quantitative estimate of an individual neonate's risk of early-onset sepsis.
80. Kaiser Permanente: Probability of Neonatal Early-Onset Sepsis Based on Maternal Risk Factors and the Infant's Clinical Presentation. <https://www.dor.kaiser.org/external/DORExternal/research/InfectionProbabilityCalculator.aspx>. [Accessed 28 December 2015]
81. Shah BA, Padbury JF. Neonatal sepsis: an old problem with new insights. *Virulence* 2014; 5:170–178.
82. Cernada M, Serna E, Bauerl C, *et al.* Genome-wide expression profiles in very low birth weight infants with neonatal sepsis. *Pediatrics* 2014; 133:e1203–e1211.
83. Wynn JL, Guthrie SO, Wong HR, *et al.* Postnatal age is a critical determinant of the neonatal host response to sepsis. *Mol Med* 2015; 21:496–504.
- Understanding the molecular signatures of host response to infection in neonates will help clinicians understand the mechanisms involved with response. Further research may clarify host gene expression utility as biomarker for infection, and provide novel concepts for interventions to improve outcomes for neonatal sepsis.
84. Griffin MP, Lake DE, Bissonette EA, *et al.* Heart rate characteristics: novel physiologic markers to predict neonatal infection and death. *Pediatrics* 2005; 116:1070–1074.
85. Sullivan BA, Grice SM, Lake DE, *et al.* Infection and other clinical correlates of abnormal heart rate characteristics in preterm infants. *J Pediatr* 2014; 164:775–780.
- Noninvasive biomarkers indicating sepsis with high sensitivity and specificity will help clinicians use antibiotics selectively, and, importantly, in a timely fashion, without having to decide to do a blood test, or wait for results from blood testing. Heart rate variability monitoring shows promise in identifying infants at risk for infection.
86. Moorman JR, Carlo WA, Kattwinkel J, *et al.* Mortality reduction by heart rate characteristic monitoring in very low birth weight neonates: a randomized trial. *J Pediatr* 2011; 159:900–906.
87. Bergin SP, Thaden JT, Ericson JE, *et al.* Neonatal *Escherichia coli* bloodstream infections: clinical outcomes and impact of initial antibiotic therapy. *Pediatr Infect Dis J* 2015; 34:933–936.
88. Ericson JE, Thaden J, Cross HR, *et al.* Antibacterial Resistance Leadership Group. No survival benefit with empirical vancomycin therapy for coagulase-negative staphylococcal bloodstream infections in infants. *Pediatr Infect Dis J* 2015; 34:371–375.
89. Thaden JT, Ericson JE, Cross H, *et al.* Survival benefit of empirical therapy for *Staphylococcus aureus* bloodstream infections in infants. *Pediatr Infect Dis J* 2015; 34:1175–1179.
- One of several recent studies from the Pediatrix Medical Group assessing outcomes for neonates with specific infections who were on specific antibiotics, this report documents improved outcomes for infants infected with *S. aureus* who were empirically treated with *S. aureus* effective antibiotics when the culture was obtained.
90. Hitron AE, Sun Y, Scarpace SB. Accuracy of empiric gentamicin dosing guidelines in neonates. *J Pediatr Pharmacol Ther* 2010; 15:264–273.
91. Tremoulet A, Le J, Poindexter B, *et al.* Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design. *Antimicrob Agents Chemother* 2014; 58:3013–3020.
- Ampicillin is the most commonly used medication in neonatology. This is the first study of pharmacokinetics of ampicillin in a strictly neonatal population.
92. Frymoyer A, Hersh AL, El-Komy MH, *et al.* Antimicrob agents chemother. Association between vancomycin trough concentration and area under the concentration-time curve in neonates. 2014; 58:6454–6461.
- Dosing strategies for vancomycin must be individualized.
93. Madigan T, Teng CB, Koshish J, *et al.* Optimization of vancomycin dosing in very low-birth-weight preterm neonates. *Am J Perinatol* 2015; 32:83–86.
94. Piper L, Smith PB, Hornik CP, *et al.* Fluconazole loading dose pharmacokinetics and safety in infants. *Pediatr Infect Dis J* 2011; 30:375–378.
- Prior to this study, recommended fluconazole dosing was probably not reaching therapeutic antifungal levels in the majority of cases. A loading dose is apparently necessary to reach antifungal levels with initial fluconazole dosing in neonates.
95. Smith PB, Cohen-Wolkowicz M, Castro LM, *et al.* Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections. *Pediatr Infect Dis J* 2011; 30:844–849.
96. Cohen-Wolkowicz M, Ouellet D, Smith PB, *et al.* Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants. *Antimicrob Agents Chemother* 2012; 56:1828–1837.
97. Cohen-Wolkowicz M, Sampson M, Bloom BT, *et al.* Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants. *Pediatr Infect Dis J* 2013; 32:956–961.
98. Cohen-Wolkowicz M, Watt KM, Zhou C, *et al.* Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants. *Antimicrob Agents Chemother* 2014; 58:2856–2865.
- The most recent of several reports from Cohen-Wolkowicz and colleagues reporting pharmacokinetic testing results on a NICU population. These reports are providing clinicians, evidence-based dosing strategies for antimicrobials in the NICU rather than extrapolations from other populations.
99. Benitz WE, Wynn JL, Polin RA. Reappraisal of guidelines for management of neonates with suspected early-onset sepsis. *J Pediatr* 2015; 166:1070–1074.
100. Polin RA, Watterberg K, Benitz W, Eichenwald E. The conundrum of early-onset sepsis. *Pediatrics* 2014; 133:1122–1123.
101. VON Choosing Antibiotics Wisely website: C <https://public.vtxford.org/quality-education/inicq-2016-choosing-antibiotics-wisely/>. [Accessed 4 December 2015]
102. Chang YJ, Choi IR, Shin WS, *et al.* The control of invasive *Candida* infection in very low birth weight infants by reduction in the use of 3rd generation cephalosporin. *Korean J Pediatr* 2013; 56:68–74.
103. Aliaga S, Clark RH, Laughon M, *et al.* Changes in the incidence of candidiasis in neonatal intensive care units. *Pediatrics* 2014; 133:236–242.
104. Horbar JD, Rogowski J, Plsek PE, *et al.* Collaborative quality improvement for neonatal intensive care. NIC/Q Project Investigators of the Vermont Oxford Network. *Pediatrics* 2001; 107:14–22.
105. Hwang JH, Choi CW, Chang YS, *et al.* The efficacy of clinical strategies to reduce nosocomial sepsis in extremely low birth weight infants. *J Korean Med Sci* 2005; 20:177–181.
106. Bizzarro MJ, Shabanova V, Baltimore RS, *et al.* Neonatal sepsis 2004–2013: the rise and fall of coagulase-negative staphylococci. *J Pediatr* 2015; 166:1193–1199.
107. Shane AL, Stoll BJ. Neonatal sepsis: progress towards improved outcomes. *J Infect* 2014; 68(Suppl 1):S24–S32.
108. Greenberg RG, Cochran KM, Smith PB, *et al.* Effect of catheter dwell time on risk of central line-associated bloodstream infection in infants. *Pediatrics* 2015; 136:1080–1086.